Last update 08 May 2025

DNA x AXL

Basic Info

Related Targets
DNAAXL

Related

1
Drugs associated with DNA x AXL
Mipasetamab Uzoptirine
Target
AXL x DNA
Mechanism
AXL inhibitors [+1]
Active Org.
Overland PharmaceuticalsOverland Pharmaceuticals
Originator Org.
ADC Therapeutics SAADC Therapeutics SA
Active Indication
Solid tumor
Inactive Indication
Advanced Malignant Solid Neoplasm
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
2
Clinical Trials associated with DNA x AXL
NCT05389462
/ Active, not recruitingPhase 1
A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Selected Advanced Solid Tumors
NCT03700294
/ TerminatedPhase 1
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients With Advanced Solid Tumors
100 Clinical Results associated with DNA x AXL
Login to view more data
100 Translational Medicine associated with DNA x AXL
Login to view more data
0 Patents (Medical) associated with DNA x AXL
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free